Vanguard Group Inc Rubius Therapeutics, Inc. Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$0.14 - $0.31 $4,006 - $8,871	-28,619 Reduced 1.68%	1,676,669 $301,000
Q3 2022 Nov 14, 2022	SELL	$0.46 - $1.29 $106,676 - $299,157	-231,905 Reduced 11.97%	1,705,288 $740,000
Q2 2022 Aug 12, 2022	SELL	$0.79 - $5.98 $310,890 - $2.35 Million	-393,532 Reduced 16.88%	1,937,193 $1.65 Million
Q1 2022 May 13, 2022	SELL	$4.25 - $10.4 $3.89 Million - $9.53 Million	-915,916 Reduced 28.21%	2,330,725 $12.8 Million
Q4 2021 Feb 14, 2022	BUY	$9.68 - $17.74 $112,617 - $206,387	11,634 Added 0.36%	3,246,641 $31.4 Million
Q3 2021 Nov 12, 2021	SELL	$17.6 - $25.91 $130,169 - $191,630	-7,396 Reduced 0.23%	3,235,007 $57.8 Million
Q2 2021 Aug 13, 2021	BUY	$22.26 - $28.43 $72.2 Million - $92.2 Million	3,242,403 New	3,242,403 $79.1 Million

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.